29.05
-0.82%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China National Medicines Corp
Its shares trade on Shanghai under the ticker 600511.SS. It has been listed since 27 November 2002. In the fiscal year to 31 December 2025, it reported revenue of CN¥52.47bn and net income of CN¥2.00bn. At that date it held total assets of CN¥36.69bn and shareholders' equity of CN¥18.54bn.
China National Medicines Co., Ltd. engages in the manufacturing and distribution of pharmaceuticals. The company is headquartered in Beijing, Beijing. The company went IPO on 2002-11-27. The firm's primary products include proprietary Chinese medicines, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, vaccines and health foods, among others. The firm is also involved in the production of pharmaceuticals and the provision of warehousing services through its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 27 Nov 2002
- Employees
- 3,080
- Website
- cncm.com.cn ↗
Leadership
Pay as last reported
- Mr. Xiuchang JiangChairman of the Board, since 2006CN¥445,000
- Mr. Fei ChenChief Financial Officer
- Ms. Lichun LuoGeneral Counsel, Acting Secretary of the BoardCN¥1.0m
- Mr. Guotao TianGeneral Manager, Director, since 2021CN¥1.6m
- Mr. Lei TangDeputy General Manager, since 2018CN¥1.6m
- Ms. Zhuoyuan XiaoDeputy General ManagerCN¥1.7m
- Ms. Tong YeDeputy General ManagerCN¥2.0m
- Ms. Xin JiangDirectorCN¥2.2m
- Ms. Xiaojuan LiDirector
- Mr. Yong LiuDirector, since 2010
- Mr. Deyong WenDirector, since 2019
- Mr. Mingyu ChenIndependent DirectorCN¥133,336
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 99
- Social
- 51
- Governance
- 57
- Direct emissions (scope 1)
- 907 t
- Energy emissions (scope 2)
- 24,918 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China National Medicines Corp Ltd employs 3080 employees in Beijing.
- The company manufactures proprietary Chinese medicines and chemical medicine preparations.
- It distributes antibiotics, vaccines, and health foods across China.
Weaknesses
- The company's primary products include narcotic drugs and psychotropic drugs.
- It relies on Beijing as its headquarters city for operations.
- The firm's IPO was on 27 November 2002, which is over 20 years ago.
Opportunities
- China's growing Health Care sector offers expansion potential for the company.
- The demand for vaccines and health foods is increasing in the Chinese market.
- The company can leverage its subsidiaries for warehousing services.
Threats
- The Health Care industry faces regulatory challenges in China.
- Competition from other pharmaceutical firms in the Chinese market.
- The company's reliance on Beijing may limit regional growth opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.